Medlior predictions for 2019 in the world of health outcomes research
January 11, 2019

Medlior’s Industry Predictions for 2019

We are looking forward to a year of innovation in health outcomes research!

After tremendous growth and success in 2018, Medlior is looking forward to tackling 2019 with a mindset of innovation and enthusiasm!

One of the reasons our team loves working at Medlior is our core purpose of positively impacting global health through rigorous research, and we look forward to contributing more towards our goal this year.

Our work within the healthcare industry offers us a unique perspective on upcoming initiatives and trends and we’ve put together 6 predictions we think you will see in 2019.

1. Expedited access to new medicines globally

Two key proposals may significantly improve timelines for access to new therapies:

  • Proposed parallel Scientific Advice between CADTH, Health Canada and NICE may allow for increased efficiency and earlier access to new therapies.
  • Health Canada and CADTH look to follow the footsteps of the EMA and EUnetHTA with new initiatives to address parallel consultation and synergies in evidence requirements between regulatory and HTA

2. RWE Data Collection

A proposed Health Canada and CADTH framework may support the funding and development of post-authorization RWE data collection, such as patient registries, to inform decision-makers and address uncertainty from clinical trials.

3. Increased utilization of digital tools

Increasing utilization of “patient-generated data” and innovation for digital tools to capture patient data from unique, community-based sources, such as apps and social media.

4. Health system disruption

The approval of CAR-T and cell therapies will likely cause massive disruption in terms of implementation. Partnership between manufacturers, providers and the health system is mandatory for the uptake of these therapies into routine clinical practice.

5. Increase in outcome-based agreements and RWE

Price negotiations will likely see an increase in outcomes-based agreements to off-set the costs for innovative medicines. Payers will need to guide the RWE requirements to support these agreements, but there are several important considerations before generating actionable data. Issues may include: lack of standardization of data elements and methodology, collaborations across jurisdictions for data pooling (particularly important for rare diseases), accurate and meaningful reporting of results to inform decision-makers who may not be well-versed in observational data.

About Medlior

At Medlior, our multidisciplinary group of experts offers substantial health system, academic and industry experience to ensure every Medlior project provides valuable insights.

Each member of the Medlior team holds an advanced degree for a clear advantage in conducting health outcomes research.

Are you looking for a source of international RWE datasets to inform future research initiatives? Subscribe to our Real World Radar today to have access to a listing of over 700 datasets.